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Abstract: A library of 53 benzimidazole derivatives, with substituents at positions 1, 2 and 5, 
were synthesized and screened against a series of reference strains of bacteria and fungi of 
medical relevance. The SAR analyses of the most promising results showed that the 
antimicrobial activity of the compounds depended on the substituents attached to the bicyclic 
heterocycle. In particular, some compounds displayed antibacterial activity against two 
methicillin-resistant Staphylococcus aureus (MRSA) strains with minimum inhibitory 
concentrations (MICs) comparable to the widely-used drug ciprofloxacin. The compounds 
have some common features; three possess 5-halo substituents; two are derivatives of  
(S)-2-ethanaminebenzimidazole; and the others are derivatives of one 2-(chloromethyl)-1H-
benzo[d]imidazole and (1H-benzo[d]imidazol-2-yl)methanethiol. The results from the 
antifungal screening were also very interesting: 23 compounds exhibited potent fungicidal 
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activity against the selected fungal strains. They displayed equivalent or greater potency  
in their MIC values than amphotericin B. The 5-halobenzimidazole derivatives could be 
considered promising broad-spectrum antimicrobial candidates that deserve further study for 
potential therapeutic applications. 




Microbial drug resistance is a serious issue, especially as increasing numbers of strains are becoming 
resistant to multiple antimicrobial agents, with some bacteria now being resistant to all available antibiotics. 
There is thus a critical need to develop new drugs with novel mechanisms of action. However, the 
investment available for such development is frequently lower than the required level. The development 
of new drug entities is hampered by several issues, notably the high cost and length of time required, as 
well as the logistical and regulatory challenges of performing the necessary clinical evaluations across 
multiple geographical areas. Therefore, a few new classes of antimicrobials have been developed since the 
late 1980s [1–3], and much research has focused only on the chemical modification of existing drugs to 
improve their potency and/or ability to overcome antibiotic resistance mechanisms. Even if this approach 
does not improve antimicrobial activity directly, it may lead to derivatives that can usefully inhibit 
virulence mechanisms [4]. 
Compounds having benzimidazole as a structural motif have been widely used in medicinal chemistry and 
drug development, and researchers are actively seeking new uses and applications of this heterocycle [5]. 
Benzimidazole-containing compounds have numerous medical and biological activities, such as 
antitumor [6] antibacterial [7–10], antifungal [11], antiviral [12–16], anticonvulsant [17], antidepressant [18], 
analgesic [19], anti-inflammatory[20] and antidiabetic properties [21]. For example, derivatives, such as 
thiabendazole, cambendazole, parbendazole, mebendazole, albendazole and flubendazole, are widely-used 
anti-helminth drugs, used to treat people and animals with gastrointestinal worm infections [22]. Two 
groups of benzimidazole derivatives, namely 5,6-dinitro- and 2-trifluromethyl derivatives, are particularly 
well known for their use as antihelminth drugs [23]. 2-Methoxycarbonylamino derivatives have shown 
good antiprotozoal activities against some protozoan parasites, such as Giardia lamblia and Entamoeba 
histolytica, by inhibiting tubulin polymerization, and hence, making these better antiprotozoal agents than 
metronidazole and albendazole [24]. Nitrogen-containing heterocyclic systems have a diverse spectrum  
of pharmacological properties. Different heterocyclic motifs can be incorporated to produce molecules 
with enhanced biological properties. Recent reports include benzimidazoles bearing the 1,3,4-oxadiazole 
moiety, which have broad spectrum antimicrobial properties [25], and molecules containing both the 
benzimidazole and indole heterocycles, which exhibit selective antibacterial activity [26]. 
A review of the literature thus suggests that there is the scope for the design of additional benzimidazole 
derivatives with antimicrobial activity, by examining the effect of a number of different functional groups. 
In this paper, we report on the synthesis of a series of benzimidazole derivatives and their antimicrobial 
activity. A detailed study of the structure-activity relationship of these derivatives will pave the road to 
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designing more potent compounds. The compounds were tested for their ability to inhibit isolates amongst 
a reference panel of 26 bacterial and 10 fungal strains, and key results are presented in Tables 1–3. 
Table 1. Benzimidazole derivatives synthesized. 
1–53 
Compound R R1 R2 
1 H H H 
2 H H CH3 
3 H H OCH3 
4 H H Cl 
5 H H Br 
6 H H F 
7 H H NO2 
8 H H CN 
9 H CH2NH2 H 
10 H CH2NH2 CH3 
11 H CH2NH2 Cl 
12 H CH2NH2 Br 
13 H CH2NH2 F 
14 H CH2NH2 NO2 
15 H CH(CH3)NH2 H 
16 H CH(CH3)NH2 CH3 
17 H CH(CH3)NH2 Cl 
18 H CH(CH3)NH2 Br 
19 H CH(CH3)NH2 F 
20 H CH2CH3 H 
21 H CH2CH3 NO2 
22 H CH2SH H 
23 H CH2SH NO2 
24 H CH2OH H 
25 H CH2OH CH3 
26 H CH2OH OCH3 
27 H CH2OH Cl 
28 H CH2OH Br 
29 H CH2OH F 
30 H CH2OH NO2 
31 H CH2OH CN 
32 H CH2Cl H 
33 H CH2Cl CH3 
34 H CH2Cl OCH3 
35 H CH2Cl Cl   
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Table 1. Cont. 
Compound R R1 R2 
36 H CH2Cl Br 
37 H CH2Cl F 
38 H CH2Cl NO2 
39 H CH2Cl CN 
40 H COOH H 
41 H COOH CH3 
42 H COOH OCH3 
43 H COOH Cl 
44 H COOH Br 
45 H COOH F 
46 H COOH NO2 
47 CH3 CH2OH H 
48 CH3 CH2OH CH3 
49 CH3 CH2OH Cl 
50 CH3 CH2OH Br 
51 CH3 CH2OH F 
52 CH3 CH2OH OCH3 
53 CH3 CH2OH NO2 
2. Results and Discussion 
2.1. Chemistry 
Our target molecules were based on benzimidazole derivatives. It is possible to design a wide range 
of potential microbial inhibitors by replacing the hydrogen at various positions of the benzimidazole ring 
with different functional groups. However, the most accessible derivatives are those with substituents at 
the 1-, 2- and 5-positions. Retrosynthetic analysis of a 2,5-disubstituted benzimidazole identified two 
fragments, which explains why these particular substituted benzimidazoles are easy to prepare (Figure 1). 
The reactions of substituted 1,2-phenylenediamines and carboxylic acids can provide access to a library 
of compounds. In this application, the design of these inhibitors focused on 5-substituted benzimidazoles 
followed by the synthesis of 2,5-disubstituted analogues based on (1H-benzimidazole-2-yl)methanol 
derivatives, (1H-benzimidazole-2-yl)alkylamines derivatives, (1H-benzimidazole-2-yl)-ethyl derivatives 
and (1H-benzimidazole-2-yl)-methanethiol derivatives (Scheme 1). The general method for the synthesis 



















Figure 1. Retrosynthetic analysis of benzimidazole. 




Scheme 1. 2,5-Substituted benzimidazole derivatives. 
The 1H-benzimidazole-2-yl)methanol derivatives were readily reacted further (oxidation, chlorination 
and N-alkylation) (Scheme 2). The hydroxyl group of (1H-benzimidazole-2-yl)methanol was converted 
into the chloromethyl through a reaction with thionyl chloride to give 2-(chloromethyl)-1H-benzimidazole 
Derivatives 32–39. The 2-chloromethylbenzimidazoless were required for the biological studies to provide 
a direct comparison with other functional groups in the 2-position of benzimidazole [28]. Benzimidazole-
2-carboxylic Acids 40–46 were readily obtained through simple oxidation of (1H-benzimidazole-2-yl)-
methanol Derivatives 24–30 using potassium permanganate. The N-methylation of Derivatives 24–30 
gave the corresponding N-methyl-5-substituted (1H-benzimidazole-2-yl)methanol derivatives 47–53. 
 
Scheme 2. Conversion of 2-methanol benzimidazole derivatives. 
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2.2. Biological Evaluation 
2.2.1. Antibacterial Activity 
Firstly, a cut-off point of an inhibition zone diameter of ≥12 mm was used to define appreciable 
antibacterial activity. Using this criteria, disc diffusion tests with the 53 compounds revealed that nine 
compounds (9, 17, 18, 22, 32, 33, 35, 36 and 52) had some degree of antibacterial activity (Table 2); with 
five exhibiting activity against representatives of at least two Staphylococcal species. Six compounds had 
activity against one or more strains of Methicillin-resistant Staphylococcus aureus (MRSA), including 
strains that were resistant to ciprofloxacin. Six compounds had some activity against S. epidermidis and 
three against the single strain of S. haemolyticus used in this study. Regarding the Gram-negative bacteria, 
only two (32 and 52) of the compounds tested were active against any of the five strains of Escherichia coli 
and none against the four strains of Pseudomonas aeruginosa. Two compounds were active against the 
single strain of Serratia marcescens, but six had some activity against the single strain of B. cepacia 
used in the screening panel. Compounds 17, 18, 22, 35 and 36 were the most active compounds overall, 
and these were selected on the basis of a broad spectrum of activity, and/or wide zones of inhibition, or 
novel chemical structure. As summarised in Table 2, these five compounds were investigated further in 
minimum inhibitory concentration (MIC) assays to quantify their activity against the reference isolates. 
Testing confirmed that they exhibited little activity against the Gram-negative species, with the exception 
of Burkholderia cepacia. However, for the Gram-positive species, there were some MICs as low as 64 and 
even 32 µg/mL. Notably, Compounds 17 and 18 had MICs comparable to that of ciprofloxacin against 
two of the MRSA strains, whilst 22 and 36 had consistent activity (MIC 32–64 µg/mL) against almost 
all of the staphylococci. This is significant and provides lead compounds for further development. 
Table 2. Antibacterial activity of selected benzimidazole derivatives against Gram-positive 
and Gram-negative bacteria (series of 2-ethanamine, 2-methanthiol, 2-chlromethyl and  
N-methyl benzimidazole derivatives). 
Bacterial Species Compound 
Diameter of the Inhibition Zone (mm) around  
Each Compound in the Agar Diffusion Test 
9 17 18 22 32 33 35 36 52 Ciprofloxacin 
Gram-Positive 
Staphylococcus aureus NCTC 6571 0 10 11 11 13 9 9 9 14 27 
Staphylococcus aureus NCTC 10399 0 12 12 16 7 7 0 0 17 33 
MRSA HG-1 0 10 11 12 0 0 0 13 13 0 
MRSA-15 NCTC 13142 0 11 10 12 0 0 9 14 15 28 
MRSA-16 NCTC 13143 0 10 13 15 0 0 10 15 13 0 
MRSA BIG 0043 0 11 10 11 9 10 9 11 12 0 
MRSA BIG 0044 0 9 12 12 10 10 9 15 12 0 
MRSA BIG 0045 0 11 11 14 0 12 9 11 13 0 
MRSA BIG 0047 0 12 13 12 0 11 9 11 13 0 
MRSA BIG 0050 0 0 12 11 0 9 9 15 13 0 
MRSA BIG 0052 0 0 13 11 0 9 9 14 12 0 
MRSA BIG 0053 0 0 11 13 0 10 9 14 13 0 
Staphylococcus epidermidis NCTC 11047 0 0 11 0 10 12 0 0 12 32 
Staphylococcus epidermidis NCTC 2749 17 9 13 13 9 10 14 9 13 35 
Staphylococcus haemolyticus NCTC 11042 0 12 10 18 11 11 0 0 15 34 
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Table 2. Cont. 
Bacterial Species Compound 
Diameter of the Inhibition Zone (mm) around  
Each Compound in the Agar Diffusion Test 
9 17 18 22 32 33 35 36 52 Ciprofloxacin 
Gram-Negative 
Burkholderia cepacia NCTC 10744 12 11 10 15 0 12 15 17 12 27 
Escherichia coli NCTC 10418 0 0 0 0 13 9 9 9 14 33 
Escherichia coli BIG 0046 0 0 0 0 9 9 8 0 9 0 
Escherichia coli BIG 0048 0 0 0 0 15 9 8 8 11 0 
Escherichia coli BIG 0049 0 0 0 0 11 0 7 8 8 0 
Escherichia coli 0051 0 0 0 0 12 9 7 0 10 0 
Pseudomonas aeruginosa NCTC 6749 0 0 0 0 10 0 0 0 10 33 
Pseudomonas aeruginosa BIG 0039 0 0 0 0 0 0 0 0 8 34 
Pseudomonas aeruginosa NCTC 10662 0 0 0 0 10 0 0 0 8 32 
Pseudomonas aeruginosa BIG 0063 0 0 0 0 10 0 0 0 9 30 
Serratia marcescens NCTC 1377 0 0 0 0 15 8 9 8 13 32 
Zone diameters indicative of antibacterial activity (i.e., ≥12 mm) are highlighted in bold. 
Interestingly, the MICs of Compounds 17 and 18 (2-ethanamine benzimidazole derivatives) against the 
investigated bacteria were similar to each other (Table 3). This suggests that the higher electronegativity 
of bromine and chlorine increased the antibacterial activity, and this was also observed by Tavman [29]. 
Table 3. MICs of the selected benzimidazole derivatives against the reference panel of Gram 
positive and Gram negative bacteria. 
Bacterial Strain 
MIC (µg/mL) per Compound 
17 18 22 35 36 Ciprofloxacin 
Gram-Positive 
Staphylococcus aureus NCTC 6571 32 32 64 128 64 ≤0.5 
Staphylococcus aureus NCTC 10399 256 256 64 128 64 >32 
MRSA HG-1 32 32 64 265 64 32 
MRSA-15 NCTC 13142 256 256 64 128 64 ≤0.5 
MRSA-16 NCTC 13143 256 256 64 256 64 32 
MRSA BIG 0043 256 256 64 256 64 >32 
MRSA BIG 0044 >512 >512 64 256 64 >32 
MRSA BIG 0045 256 256 64 256 >512 8 
MRSA BIG 0047 256 256 64 256 64 8 
MRSA BIG 0050 32 32 64 256 64 32 
MRSA BIG 0052 256 256 64 256 64 ≤0.5 
MRSA BIG 0053 256 256 64 256 64 >32 
Staphylococcus epidermidis NCTC 11047 256 256 32 256 32 ≤0.5 
Staphylococcus epidermidis NCTC 2749 256 256 64 256 64 ≤0.5 
Staphylococcus haemolyticus NCTC 11042 256 265 32 256 32 8 
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Table 3. Cont. 
Bacterial Strain 
MIC (µg/mL) per Compound 
17 18 22 35 36 Ciprofloxacin 
Gram-Negative 
Burkholderia cepacia NCTC 10744 32 32 64 256 64 ≤0.5 
Escherichia coli NCTC 10418 >512 >512 512 >512 >512 ≤0.5 
Escherichia coli BIG 0046 >512 >512 >512 >512 >512 32 
Escherichia coli BIG 0048 >512 >512 512 >512 >512 8 
Escherichia coli BIG 0049 >512 >512 >512 >512 >512 8 
Escherichia coli BIG 0051 >512 >512 >512 >512 >512 32 
Pseudomonas aeruginosa NCTC 6749 >512 >512 >512 512 265 ≤0.5 
Pseudomonas aeruginosa BIG 0039 >512 >512 >512 512 512 ≤0.5 
Pseudomonas aeruginosa NCTC 10662 >512 >512 >512 512 512 ≤0.5 
Pseudomonas aeruginosa BIG 0063 >512 >512 >512 512 512 ≤0.5 
Serratia marcescens NCTC 1377 >512 >512 >512 >512 >512 ≤0.5 
Good activity, relative to the MIC of ciprofloxacin, is indicated in bold. The results are the average of three 
independent readings. 
For the 2-methanthiol benzimidazole derivatives (22–23, Scheme 1), the unsubstituted derivative at 
position 5, Compound 22, was selectively active against all of the Gram-positive bacteria with an MIC of 
32 µg/mL against S. epidermidis NCTC 11047 and S. haemolyticus NCTC 11042 and MIC 64 µg/m against 
the other staphylococci plus B. cepacia (Table 3). The inhibitory activity decreases when position 5 is 
methylated as in Compound 23 (>512 MIC µg/mL). This was also observed by Podunavac-Kuzmanovic 
and Cvetkovic [30], who found that the unsubstituted analogue was more potent than the methyl analogues 
of the 2-aminobenzimidazole against strains of Bacillus cereus, Staphylococcus aureus, Sarcina lutea 
and Pseudomonas aeruginosa. 
From the series of 2-chloromethyl benzimidazole derivatives (Scheme 2), 36 (5-Br) was the most active 
compound with inhibition zone diameters of 13–17 mm. The largest zones of inhibition (17 mm and 15 mm 
diameter) were exhibited by Compounds 35 (5-Cl) and 36, respectively, against Burkholderia cepacia 
NCTC 10744. Only 35 and 36 were capable of inhibiting some strains at a concentration below 256 μg/mL. 
As shown in Table 3, Compound 36, the brominated derivative, was more active than Compound 35, 
which is the chlorinated derivative. This could support the hypothesis that there is a direct relationship 
between biological activity and the electron withdrawing effect [29]. 
2.2.2. Antifungal Activity 
The well diffusion tests of the 53 compounds against the fungi revealed very interesting results:  
21 compounds were active against Aspergillus clavatus RCMB 2593; 28 had some activity against 
Aspergillus fumigatus RCMB 02564; 26 compounds were active against Penicillium marneffei RCMB 
01267; 22 compounds were active against Mucor circinelloides RCMB 07328; 20 compounds were 
active against Absidia corymbifera RCMB 09635; 20 compounds were active against Syncephalastrum 
racemosum RCMB 05922; 29 compounds were active against Candida albicans RCMB 05035;  
29 compounds were active against Candida tropicalis RCMB 05049; 27 compounds were active against 
Candida parapsilosis RCMB 05065; 13 compounds had some activity against Candida krusei RCMB 
05051; 14 compounds had no detectable antifungal activity. 
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Amphotericin B was used as a positive control for the antifungal testing. The intention was not to 
compare activity on a molar basis, since such a comparison does not necessarily have biological validity 
when comparing compounds with very different modes of action or solubility in diffusion assays. This 
allowed us to identify the compounds with the most promising activity, which could be looked at in 
more detail in further studies. 
Tables 4 and 5 summarise the results for the 23 compounds that were most active against the fungal 
strains used. The antifungal screening of the series of 2-ethanamine benzimidazole Derivatives 9–19 
showed remarkable antifungal activities against both unicellular and filamentous fungi (Table 4). 
However, Compound 5 (5-Br) showed the highest antifungal activity; with a 29-mm zone of inhibition 
against Candida parapsilosis RCMB 05065 and 26 mm against Candida albicans RCMB 05035, 
Candida tropicalis RCMB 05049 and Aspergillus fumigatus RCMB 02564 (Table 4). Seven compounds, 
2–6, 14 and 20, from the series of 5-substituted benzimidazole derivatives also showed promising 
antifungal activity (Table 4). 
Interestingly, all of the selected 23 compounds showed antifungal activity against both the unicellular 
and filamentous fungi (Table 4). Moreover, the minimum inhibitory concentration (MIC) of some 
compounds, against certain fungal species, was better (i.e., lower) than that of the reference drug (Table 5). 
This suggests that when there is no substituent at position 2 and an electron withdrawing substituent at 
position 5, the antifungal activity is increased (Tables 4 and 5). This confirms the hypothesis that there is 
a direct relationship between the antifungal activity and the electron withdrawing effect of substituents. 
Compound 5 (5-Br) was active against the selected strains with MIC equivalent to half that exhibited by 
amphotericin B [31]. 
The antifungal screening of the series of 2-alkylamine benzimidazole derivatives (9–19, Scheme 1) 
showed interesting antifungal activity for the compounds. Significant activity was observed for 
Compounds 11 (5-Cl) and 14 (5-NO2), especially against Mucor circinelloides RCMB 07328 with low 
MICs of 3.9 and 0.49 µg/mL, respectively. However, no activity was observed for the 5-bromo analogue 
12. Both Compounds 11 and 14 showed remarkable antifungal activity that was almost similar to the 
reference drug, and interestingly, Compound 14 was three-fold as potent as the amphotericin B against 
Mucor circinelloides RCMB 07328. This suggests that the more electrons withdrawing the substituent 
there are, the higher the antifungal activity (Table 5). Furthermore, Compounds 11 (5-Cl), 13 (5-F), 14  
(5-NO2) and 15 (5-H) showed good activity against Candida parapsilosis RCMB 05065; with a MIC 
range of 1.95–0.06 µg/mL, which is for Compounds 11 and 15 equivalent to the MIC of amphotericin B. 
Compound 13, the 5-fluoro analogue, was three-times more potent, while 14 (5-NO2) was five-fold more 
potent than the control drug against Candida parapsilosis RCMB 05065. This suggests that when the 
electron withdrawing effect increases, the antifungal effect also increases. 
Compound 27 (5-Br), from the series of 2-methanol benzimidazole derivatives (Scheme 2), exhibited 
promising antifungal activity against Absidia corymbifera RCMB 09635, Syncephalastrum racemosum 
RCMB 05922 and Candida krusei RCMB 05051 with MICs equivalent to the reference, and two-fold the 
latter’s potency against Candida parapsilosis RCMB 05065. This suggests that the more electronegative 
bromine increases the antifungal activity (Table 5) [29]. 
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Table 4. Antifungal activity of the benzimidazole derivatives against unicellular and filamentous fungi in the well diffusion assay. 
Fungal Strain 
Diameter of Zone of Inhibition (mm) around Each Compound 
2 3 4 5 6 7 11 13 14 15 20 22 27 28 33 37 38 42 43 44 51 52 53 Am. B 
Unicellular 
Candida albicans  
RCMB 05035 
21 21 24 26 23 21 21 20 22 19 23 17 20 18 19 17 22 17 19 20 19 21 22 22 
Candida krusei  
RCMB 05051 
17 16 19 19 18 14 14 12 17 14 20 17 19 0 0 0 18 0 0 0 0 21 22 19 
Candida parapsilosis  
RCMB 05065 
21 21 25 29 23 19 19 22 24 19 20 15 21 19 21 18 22 18 16 20 16 18 18 18 
Candida tropicalis  
RCMB 05049 
22 22 25 26 25 21 20 22 22 19 21 15 21 19 20 18 22 18 20 19 20 22 24 25 
Filamentous 
Absidia corymbifera  
RCMB 09635 
21 21 22 25 23 15 14 19 21 14 0 0 19 19 19 17 20 16 18 18 20 0 0 20 
Aspergillus clavatus  
RCMB 02593 
20 21 23 23 23 17 19 19 21 17 23 19 18 14 15 15 20 14 16 15 18 22 23 22 
Aspergillus fumigatus  
RCMB 02564 
22 21 24 26 23 19 19 20 23 19 23 18 17 16 17 14 20 16 17 17 18 20 21 24 
Mucor circinelloides  
RCMB 07328 
20 21 21 23 21 17 18 17 21 17 24 19 15 17 18 14 18 12 14 14 20 23 25 18 
Penicillium marneffei  
RCMB 01267 
19 19 22 25 23 17 16 13 19 15 21 16 17 18 17 18 20 15 16 17 19 21 22 21 
Syncephalastrum racemosum  
RCMB 05922 
19 19 20 20 19 13 18 18 19 17 24 21 20 0 0 0 19 0 0 0 0 23 24 20 
Good activity, relative to the diameter of the zone of inhibition obtained with amphotericin B (i.e., a diameter ≥ amphotericin B (Am. B)), is indicated in bold.   
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Table 5. MICs of the tested compounds against unicellular and filamentous fungi. 
Fungal Strain 
MIC (µg/mL) per Compound 
2 3 4 5 6 7 11 13 14 15 20 22 27 28 33 37 38 42 43 44 51 52 53 Am. B 
Unicellular  
Candida albicans  
RCMB  05035 
0.49 0.98 0.03 0.007 0.03 0.49 0.49 0.49 0.24 1.95 0.24 31.3 0.98 3.9 1.95 7.8 0.24 7.8 0.98 0.98 0.98 0.98 0.98 0.12 
Candida krusei  
RCMB  05051 
7.8 15.6 1.95 0.98 0.98 31.25 62.5 31.3 7.8 62.5 1.95 15.6 0.98 >500 >500 >500 1.95 >500 >500 >500 >500 0.98 0.94 0.98 
Candida parapsilosis 
RCMB 05065 
0.24 0.12 0.03 0.003 0.06 0.98 1.95 0.24 0.06 1.95 1.95 125 0.49 1.95 0.24 1.95 0.12 1.95 0.98 0.98 15.6 7.8 7.8 1.95 
Candida tropicalis  
RCMB 05049 
0.24 0.24 0.02 0.007 0.06 0.49 0.98 0.24 0.12 0.98 1.95 62.5 0.49 1.95 0.49 3.9 0.12 3.9 1.95 1.95 0.49 0.49 0.12 0.02 
Filamentous  
Absidia corymbifera  
RCMB 09635 
0.24 0.24 0.12 0.03 0.06 15.63 31.3 1.95 0.49 62.5 >500 >500 0.98 3.9 1.95 7.8 0.98 7.8 7.8 3.9 0.98 >500 >500 0.98 
Aspergillus clavatus  
RCMB 02593 
0.49 0.98 0.12 0.06 0.12 3.9 1.95 1.95 0.24 3.9 0.24 3.9 1.95 62.5 31.3 31.3 0.98 62.5 15.6 31.3 3.9 0.49 0.24 0.12 
Aspergillus fumigatus 
RCMB 02564 
0.24 0.24 0.06 0.02 0.06 1.95 1.95 0.98 0.12 1.95 0.49 7.8 3.9 15.6 7.8 62.5 0.49 15.6 7.8 7.8 1.95 1.95 0.98 0.06 
Mucor circinelloides 
RCMB 07328 
0.49 0.49 0.24 0.12 0.12 7.8 3.9 7.8 0.49 15.6 0.12 1.95 31.3 7.8 1.95 62.5 1.95 125 62.5 62.5 0.98 0.24 0.12 3.9 
Penicillium marneffei 
RCMB 01267 




1.95 1.95 0.98 0.98 0.98 125 3.9 3.9 0.98 3.9 0.24 0.98 0.98 >500 >500 >500 1.95 >500 >500 >500 >500 0.24 0.12 0.98 
Good activity, relative to the MIC of amphotericin B (Am. B), is indicated in bold. The results are the average of three independent readings. 
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In the 2-carboxylic acid benzimidazole series (Scheme 2), good antifungal activity was obtained for 
two compounds, 43 (5-Cl) and 44 (5-Br), with a MIC of 0.98 µg/mL only against Candida parapsilosis 
RCMB 05065, which is twice the potency exhibited by the reference drug. However, when comparing 
these results to their unsubstituted (at position 2) analogues from series of 5-substituted benzimidazoles 
(5, 5-Br), the latter compounds were more active antifungals. Therefore, this result confirmed that the 
activity is dependent on the halogen substituents at position 5 (Table 5) [29]. 
Antifungal activity for two compounds in the 2-chloromethyl benzimidazole series (Scheme 2), 33 
(5-Me) and 38 (5-NO2), showed MICs of 1.95 µg/mL against Mucor circinelloides RCMB 07328, which 
is one-fold as potent as amphotericin B. In addition, the MICs for these compounds were higher than the 
standard drug by three- to four-fold against Candida parapsilosis RCMB 05065 (Table 5). This could 
be explained, in the case of 38 (5-NO2), which was more active than the methyl derivative 33, by the 
presence of the highly electron withdrawing substituent. As a result, Compound 38 (5-NO2) is almost 
two times as active as Compound 33 (5-Me) (Table 5). 
Compound 20 (5-H), from the 2-ethylbenzimidazole series (Scheme 1), exhibited good activity 
against Mucor circinelloides RCMB 07328 (MIC of 0.12 µg/mL; five-fold the potency of amphotericin B) 
and against Syncephalastrum racemosum RCMB 05922 (MIC of 0.24 µg/mL; three-fold the potency of 
amphotericin B) (Table 5). Interestingly, Compound 20, which is unsubstituted at position 5, showed 
promising activity, while the nitro derivative 21 was inactive (Table 5). Surprisingly, the inhibition 
activity decreases when the electron withdrawing effect of the substituent at position 5 increases; this is 
in contrast to previous results [32]. 
3. Experimental Section 
3.1. Chemistry: General Methods 
The melting points (m.p.) were determined using a Gallenkamp melting point apparatus. The IR 
spectra were recorded in KBr discs on a Nicolet 140 FTIR spectrophotometer (νmax in cm−1). 1H- and 
13C-NMR spectra were recorded using a Bruker DPX400 spectrometer. Coupling constants are given in 
Hertz (Hz). Deuterated solvents were obtained from Goss Scientific Instruments. Deuterated chloroform 
was stored over 4 Å molecular sieves. DMSO-d6 and D2O were stored in silica gel desiccators. The mass 
spectra were obtained on electron impact using an AEI MS902 mass spectrometer. Elemental analysis 
was carried out by the microanalysis service using 2 mg of the sample (MEDAC LTD, Analytical and 
Chemical Consultancy Services, Surrey, UK). Spectral data (IR, NMR and mass spectra) confirmed the 
structures of the compounds. 
The purity of all of the compounds was established by 1H- and 13C-NMR spectroscopy. All of the known 
compounds were identified by comparing their analytical and physicochemical data with previously 
reported data. The data for the compounds is provided in the Supplementary Information.   
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3.2. Screening for Antibacterial Activity 
3.2.1. Bacterial Strains Used in This Project 
All reference and clinical strains were obtained from Dr. Anna Snelling, University of Bradford. 
Overall, 15 strains of Staphylococcus spp. (including 2 × S. aureus, 10 × MRSA, 2 × S. epidermidis and 
1 × S. haemolyticus), 5 strains of E. coli, 4 strains of Ps. aeruginosa, 1 strain of Serratia marcescens and 
1 strain of Burkholderia cepacia were used. 
3.2.2. Screening for Antibacterial Activity by the Disc Diffusion Method 
Disc diffusion assays for antimicrobial susceptibility testing were carried out in-line with the standard 
method first described by Bauer (1966), to assess if the compounds had any appreciable antibacterial 
activities. The broad spectrum antibiotic ciprofloxacin was included in these qualitative tests as a comparator 
and positive control. Bacterial suspensions were prepared from fresh, overnight, agar cultures in sterile 
distilled water and adjusted to a 0.5 McFarland turbidity standard (Remel, Lenexa, KS, USA). These 
suspensions were used to seed Iso-sensitest agar (Oxoid, Hampshire, UK) plates evenly using a sterile 
swab [33]. 
For test compounds, each was dissolved to 10 mg/mL in DMSO, and different amounts of each 
(typically 10, 100 and 200 µg) were loaded from the working stock solution onto 6-mm diameter sterile 
Whatmann paper discs (Fisher Scientific, Loughborough, UK) and allowed to dry. The loaded discs were 
placed flat on the surface of the agar lawns. Each test plate was comprised of five discs: three impregnated, 
one positive control (ciprofloxacin 5 µg) and one negative control (impregnated with 20 µL of 100% 
DMSO). The plates were incubated at 37 °C for 24 h. At the end of incubation, the plates were examined 
for zones of inhibition. Diameters of inhibition zones were measured (in mm) and recorded. If any activity 
was observed, the test was repeated on a separate day, using another fresh culture. 
3.2.3. Determination of Minimum Inhibitory Concentration of Compounds against Bacterial Strains 
For quantitative assessment of activity, the MICs of the synthesised compounds plus ciprofloxacin 
were determined by the agar dilution method using Iso-sensitest agar. Agar dilution was in the range of 
0.5–512 µg/mL of each compound, in doubling dilutions. Iso-sensitest agar was sterilised in 19-mL aliquots, 
using sufficient base powder for 20 mL. Once it had cooled to approximately 50 °C, an appropriate amount 
of the test compound was added in a volume of 1 mL, to give the desired final concentration per plate. 
Bacterial suspensions were prepared as in the previous section. 
Strains were seeded (~10 µL) on to the freshly-prepared MIC agar plates using a multi-point inoculator 
(Denley, Guangzhou, China). After briefly allowing the inocula to dry, the plates were incubated 
overnight at 37 °C and the MIC was recorded as the lowest concentration of compound that inhibited 
bacterial growth completely, as indicated by the absence of any visible growth in the inoculation spot 
on the agar surface. 
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3.3. Screening for Antifungal Activity 
3.3.1. Fungal Strains Used in This Project 
The strains were obtained from the Regional Center for Mycology and Biotechnology (RCMB),  
Al-Azhar University, Cairo, Egypt, and this part of the practical work was done there, as well. Reference 
isolates for the antifungal screening; included representatives of unicellular fungi, namely Candida albicans 
RCMB 05035, Candida krusei RCMB 05051, Candida parapsilosis RCMB 05065 and Candida tropicalis 
RCMB 05049, and filamentous fungi, namely Absidia corymbifera RCMB 09635, Aspergillus clavatus 
RCMB 2593, Aspergillus fumigatus RCMB 02564, Mucor circinelloides RCMB 07328, Mucor circinelloides 
RCMB 07328, Absidia corymbifera RCMB 09635, Penicillium marneffei RCMB 01267 and 
Syncephalastrum racemosum RCMB 05922. 
3.3.2. Screening for Antifungal Activity by the Well Diffusion Method 
A qualitative assessment of antifungal activity was determined by the well diffusion method according 
to the National Committee for Clinical Laboratory Standards (NCCLS) methodology (National Committee 
for Clinical Laboratory Standards, 1993). Petri dishes containing 20 mL of malt extract agar (Oxoid) 
were seeded with 2–3 day old cultures of fungal inoculums (suspensions of spores in sterile water). Wells 
(6 mm in diameter) were cut into the agar with a sterile cork borer, and 50 μL of compound diluted in 
DMSO were added at a concentration of 5 mg/mL (250 μg per well). Plates were incubated at 37 °C 
(unicellular strains) or 28 °C (filamentous strains) for 3–7 days depending on the growth rate of each 
strain. Antifungal activity was determined based on the measurement of the diameter of the inhibition 
zone formed around each well. 
3.3.3. Determination of Minimum Inhibitory Concentration of Compounds against Fungal Strains 
For quantitative assessment of activity, chemical compounds showing activity in the well diffusion 
tests were diluted in DMSO, and then serial doubling dilutions were made in sterile growth media.  
The commonly-used antifungal drug amphotericin B (Sigma-Aldrich A9528, St. Louis, MO, USA) was 
included as a comparator. Dilutions were placed in separate wells of a 96-well microtitre tray (Sarstedt). 
A volume of standardized inoculum equal to the volume of the diluted compound was added to each well, 
bringing the microbial concentration to approximately 5 × 105 cells per mL. The trays were incubated at a 
temperature appropriate for the test species (28 °C or 37 °C), for a pre-set period (2–3 days). After 
incubation, the series of dilution wells was observed for fungal growth, usually indicated by turbidity 
and/or a pellet of fungi in the bottom of the well. For each test compound, the lowest concentration that 
completely inhibited growth was recorded as its minimum inhibitory concentration (MIC). 
4. Conclusions 
A series 53 compounds were synthesized based on the 2-benzimidazole nucleus. While none of the 
compounds were novel, 47 of them were herein tested against a panel of strains of bacteria and fungi for 
the first time. Infections caused by MRSA variants of S. aureus are particularly difficult to treat, as the 
strains are resistant to β-lactams and often manifest resistance to other classes of drug, too, such as the 
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fluoroquinolones. Thus, compounds active against the MRSA strains used in this study can be considered 
promising lead compounds. In terms of the SAR, the key factor in this case is the presence of the chlorine 
or bromine substituent at position 5 of the benzimidazole ring, and the presence of CH(CH3)NH2 or 
CH2Cl at position 2. Moreover, the presence of CH2SH at position 2 (H at position 5) proved effective for 
antimicrobial activity. Derivatives with CH2NH2 were not active against bacteria, but when a branched 
methyl group is added (CH(CH3)NH2), the antibacterial activity is improved. The latter compounds were 
prepared from S-alanine. Therefore, the product, which is also chiral, showed variable activity against the 
MRSA species. Chirality is a feature for many drugs, with one of the stereoisomers active biologically and 
the other inactive or even toxic. Therefore, the chirality has a significant impact on enhancing the biological 
activity of the compound. However, as in the case of the antifungal assay, and according to the SAR study, 
an extremely important factor is the nature of the substituent attached to the aromatic ring. The presence of 
the halogen atom (Cl, Br, F) at position 5, increased the antifungal activity. For the 5-nitro derivative, the 
presence of CH2NH2 at position 2 increased the activity. The N-methylated-2-methanolbenzimidazole 
derivatives were more active than the unmethylated analogues, and this is observed when the substituent 
at position 5 was F, OMe or NO2. To summarise, according to the SAR analysis, it can be concluded  
that some derivatives of benzimidazole offer significant possibilities for the development of new  
broad-spectrum antimicrobial agents. Through appropriate modification and fine-tuning of substituents 
at positions 1, 2 and 5, new microbial inhibitors are possible, although thorough toxicological evaluation 
will be needed to assess their utility for medicinal use. To summarise, according to the SAR analysis,  
it can be concluded that some derivatives of benzimidazole offer significant possibilities for the 
development of new broad-spectrum antimicrobial agents. The structures of our lead compounds are 
shown in (Figures 2 and 3). 
 
Figure 2. Promising antibacterial derivatives. 
 
Figure 3. Promising antifungal derivatives. 
Supplementary Materials 
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/08/15206/s1.   




This research project was supported by a grant from the “Research Centre of the Centre for Female 
Scientific and Medical Colleges”, Deanship of Scientific Research, King Saud University. 
Author Contributions 
N.K. and A.M.S. designed and supervised the research; F.A.S.A. performed the research; N.K., 
A.M.S. and F.A.S.A. wrote the paper; M.E.Z., A.M.A. and A.S.A. assisted with additional tests and data 
analysis. All authors read and approved the final manuscript. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Franco, B.E.; Martínez, M.A.; Rodríguez, M.S.; Wertheimer, A.I. The determinants of the antibiotic 
resistance process. Infect. Drug Resist. 2009, 2, 1–11. 
2. Barrett, C.T.; Barrett, J.F. Antibacterials: Are the new entries enough to deal with the emerging 
resistance problems? Curr. Opin. Biotechnol. 2003, 14, 621–626. 
3. Cole, S.T. Who will develop new antibacterial agents? Philos. Trans. R. Soc. B Biol. Sci. 2014, 369, 
doi:10.1098/rstb.2013.0430. 
4. Imperi, F.; Massai, F.; Facchini, M.; Frangipani, E.; Visaggio, D.; Leoni, L.; Bragonzi, A.;  
Visca, P. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa 
pathogenicity. Proc. Natl. Acad. Sci. USA 2013, 110, 7458–7463. 
5. Wang, M.; Han, X.; Zhou, Z. New substituted benzimidazole derivatives: A patent review  
(2013–2014). Expert Opin. Ther. Pat. 2015, 25, 595–612. 
6. Soderlind, K.J.; Gorodetsky, B.; Singh, A.K.; Bachur, N.R.; Miller, G.G.; Lown, J.W. Bis-benzimidazole 
anticancer agents: Targeting human tumour helicases. Anticancer Drug Des. 1999, 14, 19–36. 
7. Kumar, K.; Awasthi, D.;Lee, S.Y. ; Cummings, J.E. ; Knudson, S.E. ; Slayden, R.A.; Ojima, I. 
Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg. Med. Chem. 2013, 
21, 3318–3326. 
8. Mentese, E.; Bektas, H.; Ulker, S.; Bekircan, O.; Kahveci, B. Microwave-assisted synthesis of new 
benzimidazole derivatives with lipase inhibition activity. J. Enzyme Inhib. Med. Chem. 2014, 29, 
64–68. 
9. Velı́k, J.; Baliharová, V.; Fink-Gremmels, J.; Bull, S.; Lamka, J.; Skálová, L. Benzimidazole drugs 
and modulation of biotransformation enzymes. Res. Vet. Sci. 2004, 76, 95–108. 
10. Janupally, R.; Jeankumar, V.U.; Bobesh, K.A.; Soni, V.; Devi, P.B.; Pulla, V.K.; Suryadevara, P.; 
Chennubhotla, K.S.; Kulkarni, P.; Yogeeswari, P.; et al. Structure-guided design and development of 
novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus. 
Bioorg. Med. Chem. 2014, 22, 5970–5987. 
11. Ke, Y.; Zhi, X.; Yu, X.; Ding, G.; Yang, C.; Xu, H. Combinatorial synthesis of benzimidazole-azo-phenol 
derivatives as antifungal agents. Comb. Chem. High Throughput Screen 2014, 17, 89–95. 
Molecules 2015, 20 15222 
 
 
12. Tonelli, M.; Paglietti, G.; Boido, V.; Sparatore, F.; Marongiu, F.; Marongiu, E.; La Colla, P.;  
Loddo, R. Antiviral activity of benzimidazole derivatives. I. Antiviral activity of 1-substituted-2-
[(benzotriazol-1/2-yl)methyl]benzimidazoles. Chem. Biodivers. 2008, 5, 2386–2401. 
13. Vitale, G.; Corona, P.; Loriga, M.; Carta, A.; Paglietti, G.; Ibba, C.; Giliberti, G.; Loddo, R.; 
Marongiu, E.; la Colla, P. Styrylbenzimidazoles. Synthesis and biological activity—Part 3. Med Chem. 
2010, 6, 70–78. 
14. Tonelli, M.; Simone, M.; Tasso, B.; Novelli, F.; Boido, V.; Sparatore, F.; Paglietti, G.; Pricl, S.; 
Giliberti, G.; Blois, S.; et al. Antiviral activity of benzimidazole derivatives. II. Antiviral activity 
of 2-phenylbenzimidazole derivatives. Bioorg. Med. Chem. 2010, 18, 2937–2953. 
15. Vitale, G.; Corona, P.; Loriga, M.; Carta, A.; Paglietti, G.; Giliberti, G.; Sanna, G.; Farci, P.; 
Marongiu, M.E.; la Colla, P. 5-Acetyl-2-arylbenzimidazoles as antiviral agents. Part 4. Eur. J.  
Med. Chem. 2012, 53, 83–97. 
16. Tonelli, M.; Novelli, F.; Tasso, B.; Vazzana, I.; Sparatore, A.; Boido, V.; Sparatore, F.;  
la Colla, P.; Sanna, G.; Giliberti, G.; et al. Antiviral activity of benzimidazole derivatives. III. Novel 
anti-CVB-5, anti-RSV and anti-Sb-1 agents. Bioorg. Med. Chem. 2014, 22, 4893–4909. 
17. Shingalapur, R.V.; Hosamani, K.M.; Keri, R.S.; Hugar, M.H. Derivatives of benzimidazole 
pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. Eur. J. Med. Chem. 
2010, 45, 1753–1759. 
18. Siddiqui, N.; Andalip; Bawa, S.; Ali, R.; Afzal, O.; Akhtar, M.J.; Azad, B.; Kumar, R. Antidepressant 
potential of nitrogen-containing heterocyclic moieties: An updated review. J. Pharm. Bioallied Sci. 
2011, 3, 194–212. 
19. Datar, P.A.; Limaye, S.A. Design and Synthesis of Mannich bases as Benzimidazole Derivatives as 
Analgesic Agents. Anti-Inflamm. Anti-Allergy Agents Med. Chem. 2015, 14, 35–46. 
20. Achar, K.C.S.; Hosamani, K.M.; Seetharamareddy, H.R. In vivo analgesic and anti-inflammatory 
activities of newly synthesized benzimidazole derivatives. Eur. J. Med. Chem. 2010, 45, 2048–2054. 
21. Bansal, Y.; Silakari, O. The therapeutic journey of benzimidazoles: A review. Bioorg. Med. Chem. 
2012, 20, 6208–6236. 
22. Cho, H.S.; Lopes, P.F. Injectable Formulation of a Macrocyclic Lactone and Levamisole. (2011): 
United States Patent NO. 20130090296. Available online: http://patentscope.wipo.int/search/en/ 
detail.jsf?docId=WO2011161209&recNum=34&maxRec=497&office=&prevFilter=&sortOption 
=&queryString=DORAMECTIN&tab=PCTDescription (accessed on 10 June 2015). 
23. Stefanska, J.Z.; Gralewska, R.; Starosciak, B.J.; Kazimierczuk, Z. Antimicrobial activity of substituted 
azoles and their nucleosides. Pharmazie 1999, 54, 879–884. 
24. Valdez, J.; Cedillo, R.; Hernández-Campos, A.; Yépez, L.; Hernández-Luis, F.; Navarrete-Vázquez, G.; 
Tapia, A.; Cortés, R.; Hernández, M.; Castillo, R. Synthesis and antiparasitic activity of 1H-benzimidazole 
derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 2221–2224. 
25. Desai, N.C.; Kotadiya, G.M. Microwave-assisted synthesis of benzimidazole bearing 1,3,4-oxadiazole 
derivatives: Screening for their in vitro antimicrobial activity. Med. Chem. Res. 2014, 23, 4021–4033. 
26. Kishore Babu, P.N.; Ramadevi, B.; Poornachandra, Y.; Ganesh Kumar, C. Synthesis, antimicrobial, 
and anticancer evaluation of novel 2-(3-methylindolyl)benzimidazole derivatives. Med. Chem. Res. 
2014, 23, 3970–3978. 
Molecules 2015, 20 15223 
 
 
27. Phillips, M.A. CCCXVII.-The formation of 2-substituted benziminazoles. J. Chem. Soc. (Resumed) 
1928, doi:10.1039/JR9280002393. 
28. Dirk, S.; Thorsten, L.L.; Philipp, L.; Martin, L.; Ralf, R.H.L.; Kirsten, A.; Klaus, R.; Gerald Juergen, R.; 
Stephan Georg, M. Alkyne compounds with MCH antagonistic activity and medicaments comprising 
these compounds. (2009), Boehringer Ingelheim Pharma GmbH and Co. KG: United States Patent 
Patent no. US 7592358 B2. Available online: http://www.lens.org/lens/patent/US_7592358_B2/ 
fulltext (accessed on 10 May 2015). 
29. Tavman, A.; Ikiz, S.; Bagcigil, A.F.; Ozgur, N.Y.; Ak, S. Preparation, characterization and antibacterial 
effect of 2-methoxy-6-(5-H/Me/Cl/NO2-1H-benzimidazol-2-yl)phenols and some transition metal 
complexes. J. Serbian Chem. Soc. 2009, 74, 537–548. 
30. Podunavac-Kuzmanovic, S.O.; Cvetkovic, D.M. Antibacterial evaluation of some benzimidazole 
derivatives and their zinc(II) complexes. J. Serbian Chem. Soc. 2007, 72, 459–466. 
31. Karuvalam, R.P.; Haridas, K.R.; Shetty, S.N. Trimethylsilyl chloride-catalyzed synthesis of substituted 
benzimidazoles using two phase system under microwave conditions, and their antimicrobial studies. 
J. Chil. Chem. Soc. 2012, 57, 1122–1125. 
32. González-Chávez, M.M.; Méndez, F.; Martínez, R.; Pérez-González, C.; Martínez-Gutiérrez, F. 
Design and Synthesis of Anti-MRSA Benzimidazolylbenzene-sulfonamides. QSAR Studies for 
Prediction of Antibacterial Activity. Molecules 2011, 16, 175–189. 
33. Bauer, R.W.; Kirby, M.D.K.; Sherris, J.C.; Turek, M. Antibiotic susceptibility testing by standard 
single disc diffusion method. Am. J. Clin. Pathol. 1966, 45, 493–496. 
Sample Availability: Samples of the compounds are not available from the authors.  
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
